Nyrada Quarterly Activities Report & Appendix 4C

Nyrada Inc. (ASX: NYR) announced its Quarterly Activities Report and Appendix 4C for the three-month period ending March 31, 2024. Nyrada Inc. drug candidate NYR-BI03, developed for treating brain injury, has demonstrated strong efficacy by rescuing an average of 42% of brain injuries in the Penumbra region. Good Laboratory Practice studies to assess the safety of NYR-BI03 in two animal species have commenced. These GLP studies include cardiac safety, pharmacology, and toxicology tests.

Phase I Human Clinical Trial Subject to completing GLP studies, Nyrada will begin a Phase I first-in-human clinical trial for NYR-BI03 in 2QFY2025. The purpose of the Phase I trial, to be conducted in Australia, will be to assess how NYR-BI03 affects the human body. As of March 31, 2024, the company has a cash position of AU$5.60 million.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com